Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Rhea-AI Summary
Cellectis (NASDAQ: CLLS) will report fourth quarter and full year 2025 financial results for the period ending December 31, 2025 on March 19, 2026 after US market close. An investor conference call and webcast will follow on March 20, 2026 at 8:00 AM ET / 1:00 PM CET.
Dial-in details and a webcast link are provided for investors to access the company’s results and business update.
Positive
- None.
Negative
- None.
News Market Reaction – CLLS
In the Mar 13 session, CLLS gained 2.70%, reflecting a moderate positive market reaction. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.0x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Share capital update | Neutral | -2.4% | Monthly report of total shares and voting rights as of Feb 28, 2026. |
| Feb 04 | Share capital update | Neutral | -1.1% | Monthly disclosure of share count and voting rights as of Jan 31, 2026. |
| Jan 08 | Strategy and pipeline | Positive | -1.6% | Outlined 2026 strategy, key CAR-T clinical catalysts, and cash runway into H2 2027. |
| Jan 05 | Share capital update | Neutral | -3.1% | Detailed total shares and voting rights as of Dec 31, 2025. |
| Dec 15 | Arbitral decision | Negative | -15.2% | Arbitral Tribunal ordered partial termination of a Servier license for UCART19 V1. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including neutral monthly capital updates and a positive 2026 strategy outline, has often been followed by negative price reactions, while clearly adverse legal news also saw a pronounced selloff.
Over the past few months, Cellectis has mainly issued administrative updates on share capital and voting rights on Dec 31, 2025, Jan 31, 2026, and Feb 28, 2026, each followed by modest declines. A more substantive update on Jan 8, 2026 detailed the 2026 strategy, including allogeneic CAR-T catalysts and a cash runway into H2 2027, yet also saw a small drop. On Dec 15, 2025, an adverse arbitral decision with Servier triggered a sharper negative reaction, underscoring sensitivity to legal developments versus routine disclosures.
Key Terms
gene-editing medical
cell and gene therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.
The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2025 results and an update on business activities. Details for the call are as follows:
Dial in information:
Domestic: +1-800-579-2543
International: +1-785-424-1789
Conference ID: CLLSFY
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1747993&tp_key=8aa72cea7f
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
